Comment on 'Population-adjusted indirect treatment comparison of maintenance PARP inhibitor with or without bevacizumab versus bevacizumab alone in women with newly diagnosed advanced ovarian cancer'. ( Ther Adv Med Oncol . 2021 Sep 30;13:17588359211049639).